



External Quality Assessment Program for Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis*

Labquality is announcing a new EQA scheme for Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis*. The scheme is suitable for different ELISA assays measuring the cell-mediated response to specific tuberculosis antigens in whole blood.

A pilot study will be conducted in September-October 2022. The pilot round will include two to three sample sets that mimic patient samples after the plasma harvesting step. We aim to cover the whole blood incubation step by including a set of preanalytical questions of a case description in conjunction with the physical samples. The participants submit their results through the electronic platform LabScala and results are processed by the EQA Coordinator. Result evaluations including comments by the Scheme Expert will be published in the final report distributed to the participants.

Round 1, 2022 will be a pilot study free of charge for a limited number of participants (sold out). Four rounds will be included in the program of 2023.

5250 Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis*

- Samples:** 2-3 lyophilized sample sets and a preanalytical case description incl questions
- Distribution:** **1, 2022 September/October** – free-of-charge pilot round
- Participation:** Limited number of samples available. The sample sets are sold out and we can only accept new registrations for a **waiting list**, if samples become available.

Please note, if you have registered through the general pilot registration link earlier this year, no further actions are needed, and you are included in the pilot study.

For more information

Labquality's customer service info@labquality.fi or

Kati Luuro

EQA Coordinator

kati.luuro@labquality.com

+358 40 661 4774

Heidi Berghäll

Development Manager

heidi.berghall@labquality.com

+358 50 356 0503